Sanofi Consumer Healthcare India Ltd
SANOFICONR NSE
Sanofi Consumer Healthcare India Ltd
HealthcareNSE: SANOFICONR BSE: 544250 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹9,971 Cr
Volatility
Moderate
P/E Ratio
37.55
EBITDA
₹327 Cr
Return on Equity
62.53%
Debt to Equity
0.06
Book Value
₹151.07
52W High
₹5,357
52W Low
₹3,975
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sanofi Consumer Healthcare India Ltd insights
30 extracted metrics + investor summaries across FY23–FY25.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 77.6%
- Company has been maintaining a healthy dividend payout of 49.3%
Weaknesses
1- Stock is trading at 28.9 times its book value
Growth Rate
Revenue Growth
21.60% ↗
Net Income Growth
32.65% ↗
Cash Flow Change
-60.18% ↘
ROE
-5.69% ↘
ROCE
-7.65% ↘
EBITDA Margin (Avg.)
-5.05% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 42d agoAI opinion · based on fundamentals
Risk medium
Sanofi Consumer Healthcare India Ltd trades at a market cap of ₹10,640 Cr with a PE of 41.3x and price-to-book of 27.76x. The company delivered TTM sales growth of 38% and profit growth of 35%, while maintaining a 3-year ROE of approximately 78% with virtually no debt on its balance sheet.
Bull Case 8
- Company is almost debt-free, providing significant financial flexibility and resilience against interest rate cycles
- Exceptional 3-year ROE of 78% indicates highly efficient capital allocation and strong competitive moat in its product portfolio
- TTM compounded sales growth of 38% demonstrates robust top-line momentum in the consumer healthcare segment
- TTM compounded profit growth of 35% shows strong earnings acceleration alongside revenue growth
- Last year ROE of 72% confirms consistent high returns are being sustained, not a one-off occurrence
- Healthy dividend payout ratio of 49.3% with a current yield of 1.62% provides regular income to shareholders
- Backed by global Sanofi parentage, offering access to R&D pipelines, brand equity, and operational best practices in consumer healthcare
- Company is expected to deliver a good upcoming quarter based on operational trends, potentially extending the growth streak
Bear Case 8
- Stock trades at 27.76x book value, an extremely elevated valuation that leaves minimal margin of safety for investors
- PE ratio of 41.3x is significantly above the broader market average, pricing in substantial future growth that must be delivered consistently
- Stock price has declined 14% over the past 1 year, indicating negative price momentum despite strong fundamentals
- Limited long-term historical data available — 5-year and 10-year CAGR figures for sales, profit, and stock returns are not reported, making long-term trend assessment difficult
- 52-week high and low data are unavailable (showing 0), limiting ability to assess current price relative to recent trading range
- Market cap of ₹10,640 Cr in a niche consumer healthcare segment may constrain institutional interest and liquidity compared to larger pharma peers
- Dividend yield of 1.62% is modest relative to the premium valuation being paid, offering limited downside protection
- High ROE of 72-78% partly reflects a very low equity base (as evidenced by 27.76x P/B), which can amplify apparent returns without proportional economic value creation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 42d ago Positives 1
- Rs 75 final dividend declared Jun 26
Sanofi Consumer Healthcare India declared a final dividend of Rs 75 per share for FY25 at its 3rd AGM held on June 26, 2026, signaling strong cash generation and shareholder return commitment.
TL;DR: Sanofi Consumer Healthcare India is returning significant cash to shareholders with a Rs 75/share dividend for FY25, reflecting healthy profitability. No headwinds or risks are visible from recent news flow. With limited public information beyond the dividend announcement, the outlook appears stable but warrants monitoring for operational updates.
Quarterly Results
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | 38% |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
| PBT | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | 25% |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 |
| EPS in Rs | — | — | — | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |
Profit & Loss
| Dec 2023 8m | Dec 2024 | Mar 2025 | Dec 2025 | TTM | |
|---|---|---|---|---|---|
| Sales | 555 | 724 | 878 | 878 | 950 |
| Expenses | 337 | 454 | 569 | 569 | 597 |
| Operating Profit | 219 | 271 | 309 | 309 | 353 |
| OPM % | 39% | 37% | 35% | 35% | 37% |
| Other Income | 2 | -15 | 25 | 25 | 20 |
| Interest | 0 | 4 | 2 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 | 13 |
| PBT | 219 | 247 | 320 | 320 | 357 |
| Tax % | 25% | 27% | 25% | 25% | — |
| Net Profit | 165 | 181 | 240 | 240 | 266 |
| EPS in Rs | — | 78.59 | 104 | 104 | 115 |
| Div. Payout % | 6% | 70% | 0% | 72% | — |
Balance Sheet
| Dec 2023 | Dec 2024 | Dec 2025 | Jun 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 23 | 23 | 23 |
| Reserves | 206 | 250 | 361 | 325 |
| Borrowings | 0 | 20 | 25 | 21 |
| Other Liabilities | 138 | 138 | 138 | 338 |
| Total Liabilities | 345 | 431 | 547 | 706 |
| Fixed Assets | 5 | 29 | 36 | 30 |
| CWIP | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 338 | 402 | 511 | 677 |
| Total Assets | 345 | 431 | 547 | 706 |
Cash Flow
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| Operating | 0 | 439 | — | 175 |
| Investing | 0 | 2 | — | 8 |
| Financing | 2 | -116 | — | -134 |
| Net Cash Flow | 2 | 325 | — | 48 |
| Free Cash Flow | -4 | 429 | — | 167 |
| CFO/OP | 2 | 208 | — | 85 |
Ratios
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| Debtor Days | 21 | 7 | — | 12 |
| Inventory Days | 232 | 80 | — | 98 |
| Days Payable | 144 | 138 | — | 126 |
| Cash Conversion Cycle | 109 | -51 | — | -16 |
| Working Capital Days | 134 | -33 | — | -4 |
| ROCE % | — | 111% | — | 90% |
Documents
1
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%. 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed. 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.
3
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute. 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.
4
Results - Financial Results For March 31, 2026
28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million. 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million.
Frequently Asked Questions about Sanofi Consumer Healthcare India Ltd
What does Sanofi Consumer Healthcare India Ltd do?
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
Where is Sanofi Consumer Healthcare India Ltd (SANOFICONR) listed?
Sanofi Consumer Healthcare India Ltd is listed on the Indian stock exchanges. It is listed on NSE: SANOFICONR and BSE: 544250. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sanofi Consumer Healthcare India Ltd belong to?
Sanofi Consumer Healthcare India Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has a market capitalisation of approximately ₹9970.88 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Sanofi Consumer Healthcare India Ltd?
The Price-to-Earnings (PE) ratio of Sanofi Consumer Healthcare India Ltd is 37.55. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sanofi Consumer Healthcare India Ltd?
Over the past 52 weeks, Sanofi Consumer Healthcare India Ltd has traded between a low of ₹3,975 and a high of ₹5,357. This range helps investors understand the stock's price volatility and recent trading levels.
Does Sanofi Consumer Healthcare India Ltd pay dividends?
Yes, Sanofi Consumer Healthcare India Ltd has a dividend yield of 1.72%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has a Return on Equity (ROE) of 62.53%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sanofi Consumer Healthcare India Ltd on Tapetide?
On Tapetide, you can view Sanofi Consumer Healthcare India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]